Seppi D - Search Results

1

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P. Rinaldi F, et al. Among authors: seppi d. Mult Scler. 2012 Nov;18(11):1640-3. doi: 10.1177/1352458512464282. Mult Scler. 2012. PMID: 23100526

2

No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.

Rinaldi L, Rinaldi F, Perini P, Calabrese M, Seppi D, Grossi P, Mattisi I, Barzon L, Mengoli C, Sanzari M, Palú G, Gallo P. Rinaldi L, et al. Among authors: seppi d. J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1345-50. doi: 10.1136/jnnp.2009.201079. Epub 2010 Jun 14. J Neurol Neurosurg Psychiatry. 2010. PMID: 20547618

3

Cortical diffusion-tensor imaging abnormalities in multiple sclerosis: a 3-year longitudinal study.

Calabrese M, Rinaldi F, Seppi D, Favaretto A, Squarcina L, Mattisi I, Perini P, Bertoldo A, Gallo P. Calabrese M, et al. Among authors: seppi d. Radiology. 2011 Dec;261(3):891-8. doi: 10.1148/radiol.11110195. Epub 2011 Oct 26. Radiology. 2011. PMID: 22031708

4

Cortical Pathology in RRMS: Taking a Cue from Four Sisters.

Calabrese M, Seppi D, Cocco E, Poretto V, Rinaldi F, Perini P, Gallo P. Calabrese M, et al. Among authors: seppi d. Mult Scler Int. 2012;2012:760254. doi: 10.1155/2012/760254. Epub 2012 Sep 27. Mult Scler Int. 2012. PMID: 23056945 Free PMC article.

5

Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.

Rinaldi F, Perini P, Atzori M, Favaretto A, Seppi D, Gallo P. Rinaldi F, et al. Among authors: seppi d. Mult Scler Int. 2015;2015:369348. doi: 10.1155/2015/369348. Epub 2015 Feb 23. Mult Scler Int. 2015. PMID: 25802758 Free PMC article.

6

Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report.

Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P. Rinaldi F, et al. Among authors: seppi d. Neurol Sci. 2011 Jan;31 Suppl 3:317-20. doi: 10.1007/s10072-010-0346-x. Neurol Sci. 2011. PMID: 20535514

7

Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.

Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P. Rinaldi F, et al. Among authors: seppi d. Mult Scler. 2012 Dec;18(12):1760-7. doi: 10.1177/1352458512447704. Epub 2012 May 8. Mult Scler. 2012. PMID: 22570359 Clinical Trial.

8

Increased incidence of multiple sclerosis in the Veneto region, Italy.

Puthenparampil M, Seppi D, Rinaldi F, Federle L, Calabrese M, Perini P, Gallo P; Multiple Sclerosis Epidemiology Veneto Study Group (MuSEV). Puthenparampil M, et al. Among authors: seppi d. Mult Scler. 2013 Apr;19(5):601-4. doi: 10.1177/1352458512461970. Mult Scler. 2013. PMID: 23599184

9

Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset.

Seppi D, Puthenparampil M, Federle L, Ruggero S, Toffanin E, Rinaldi F, Perini P, Gallo P. Seppi D, et al. J Neuroimmunol. 2014 May 15;270(1-2):56-60. doi: 10.1016/j.jneuroim.2014.02.014. Epub 2014 Mar 6. J Neuroimmunol. 2014. PMID: 24657029

10

Enlarged Virchow Robin spaces associate with cognitive decline in multiple sclerosis.

Favaretto A, Lazzarotto A, Riccardi A, Pravato S, Margoni M, Causin F, Anglani MG, Seppi D, Poggiali D, Gallo P. Favaretto A, et al. Among authors: seppi d. PLoS One. 2017 Oct 18;12(10):e0185626. doi: 10.1371/journal.pone.0185626. eCollection 2017. PLoS One. 2017. PMID: 29045421 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page